22 Apr

Global Clinical Trials take advantage of significant Australian R&D tax incentives

Australia and New Zealand are well-established regions for international clinical trials.  Global sponsors understand the region’s ability to deliver quality research outcomes; rapid start-up, recruitment and participant retention, streamlined ethics and regulatory pathways, internationally accepted quality data from world-leading research facilities and Investigators.  These key regional benefits are all delivered cost-effectively, with the added bonus of the attractive AU Government R&D Incentive, encouraging global companies to conduct research activities in Australia. 

Clinical trials are high cost and high risk, so it makes sense to maximise the time and cost advantages of the Australian environment to deliver high quality, regulatory ready data. 

Sponsors often struggle to understand the AU R&D Incentive program and an early understanding is important to ensure that appropriate structures and decisions are made. PharmaSols in conjunction with Acclime have developed a high-level summary of information new global biotech’s should consider when reviewing the AU R&D program.

AU R&D - A Quick Guide and Overview

The AU R&D incentive is one of many positive factors for conducting research in this region.  Sponsors come to realise that the time savings delivered by this region often outweigh the AU R&D rebate $ value claimed. 

“Other global regions can take 6-12 months longer in the start-up phase of a clinical trial. If you think about it, every day a clinical trial is delayed costs in terms of lost revenue. That cost is often more significant than any tax rebate.” - Nicole Elliott Strategy & Finance PharmaSols

“The AU R&D incentive is the cherry on the top of a sundae of reasons to conduct clinical trials in Australia.” – Liz Austin, Austin Legal 

  1. Get early AU R&D Tax Advice
    There are strict requirements that need to be met in order to claim the AU R&D tax incentive, so you’ll need to engage the experts from the outset – documentation is key. 
  1. Understand key R&D terms

    a. Aggregated Turnover:  determines the rate
    Most global biotech’s qualify in the under AUD$20m aggregated turnover category and therefore qualify for the 43.5% cash refund. This aggregated turnover revenue definition might include venture capital/investor/shareholder companies and this can push companies into the higher aggregated turnover category. This is often overlooked. Whilst your R&D spend may still qualify for the R&D tax incentive, in this case, it would come in the form of a tax offset (rather than a cash rebate)

    b. AU Eligible Entity:  set up an AU Eligible entity before costs are incurred
    For most global companies, this involves setting up a new AU entity and registering with the ATO/Dept of Industry. The incorporation of a new AU entity is a simple, inexpensive process that can normally be completed within 24-48hours. As only R&D costs incurred after registration of a company qualify, this is a vital first step that is often overlooked in the hurry to start up a new clinical trial.

    c. Document your parent-subsidiary relationship
    Your parent-AU subsidiary relationship will determine whether you are eligible to claim the R&D tax incentive and ultimately, the net value of the incentive. There are 2 primary relationships that provide access to the incentive:  an ‘agency’ relationship or an ‘entrepreneurial’ relationship. Under an agency model, the AU entity is acting as an agent on behalf of the parent company. Under an entrepreneurial model, the AU entity is the major benefactor of the R&D and receives material beneficial interest in the results and a return on investment that an arm’s length entrepreneur would expect to receive for taking on the risk of conducting the trials.  Regardless of the relationship you choose, you will need a legal agreement to evidence that your chosen relationship meets the requirements of the R&D tax incentive and complies with Australian transfer pricing principles.

    “AU R&D Advisors, like Acclime, are an important part of the early stages of this R&D program. Often sponsors think it’s as simple as setting up a new AU registered company, but it is so much more complex than this. Get advice upfront and set up the appropriate structures right at the start.” - Nicole Elliott Strategy & Finance PharmaSols.

    d. Eligible R&D activities: AU Govt recognises Phase 1-3 clinical trials

    Phase 1, 2 and 3 clinical trials generally satisfy the R&D eligible activities definition. The AU govt has guidance and also recently released a determination noting that such trials should qualify for the R&D incentive.
    Generally, only R&D activities conducted in AU qualify.

    Overseas (ex Australia) R&D activities may qualify upon receipt of an Overseas Finding from the Dept of Industry. Applications for Overseas Findings need to be submitted in the year the overseas activities commence in order to claim the expense.

    There are strict criteria for the grant of an Overseas Finding. Your application will need to establish that the overseas R&D activity(ies) meets the following conditions:

    1. overseas R&D has a significant scientific link to the AU R&D activities
    2. overseas R&D activity must be unable to be conducted in AU.This includes lack of access to facility, expertise, specific population or that equipment or activities contravene AU biosecurity laws. Generally speaking, cost is not an acceptable reason; and
    3. anticipated expenditure on all overseas R&D activities must be less than AU R&D activities
    4. there must be a core activity wholly undertaken in Australia.

      Evidence is required as part of an application and an Overseas Finding application is made on a case-by-case basis. Overseas Findings cover expenditure in the year of application and 2 years following (for a total of 3 years).

      Overseas Finding applications should be prepared by a tax advisor and the process can be expensive and time-consuming, with no guarantee of success. If your clinical trial requires critical ex Australia activities and you think those activities meet the above criteria, speak to a tax advisor for a preliminary view on your likelihood of success of an application for an Overseas Finding.  
      When do I claim? When do I get the cash rebate?

e. When do I claim? When do I get the cash rebate?

    • Registered R&D activities with the Dept of Industry
    • Income Tax Return submitted
    • Refundable amounts are generally paid 6-10 weeks from the date of Income Tax Return lodgement.

The AU R&D Tax Incentive program supports Australia as an attractive region for global sponsors. 

There is however potential for global sponsors to make critical errors when stepping through this complicated framework.  Early advice from experts, like Acclime, is a good investment for every global sponsor who may be interested in conducting a clinical trial in this region with the support of the R&D tax incentive.

“PharmaSols are experts at delivering clinical trials. We know enough about the AU R&D program to know, that you need an AU R&D expert. It can be a simple process, but you need a good advisor.” - Nicole Elliott Strategy & Finance PharmaSols

Vital Steps:

  1. Talk with an R&D Advisor
  2. Confirm Eligible AU R&D Entity
  3. Get your legal documents in place to evidence entitlement to claim 
  4. Review agreements with third-party suppliers (e.g., CROs) to identify any R&D tax incentive risks 
  5. Register R&D activities with the Dept of Industry
  6. Review R&D expenditure and supporting documentation

ATO = Australian Tax OfficeDept of Industry = Department of Industry, Science, Energy and Resources, previously known as AusIndustry.

Find out more >>>R&D Fact Sheet

Contact >>> Acclime https://australia.acclime.com/conducting-rd/

Please note the above is general information and not formal R&D tax incentive and tax advice.  We would strongly recommend formal advice be sought from a suitably qualified and experienced R&D advisor & tax advisor before conducting any R&D activities to ensure all of the requirements of the R&D tax incentive are met.

Other News

Innovative Strategies For Successful Drug Development

We are living in an extraordinary time of scientific innovation, where our understanding of biology is exploding and our ability to improve human health is unprecedented with new opportunities to develop new innovative medicines and devices.

Read more
ANZ Region Rescues Stalled Global Clinical Trials

Randomized, controlled trials are considered the gold standard for evaluating the safety and efficacy of potential new medicines and therapies, as they provide a rigorous and unbiased way to compare treatments to placebo or standard care.

Read more
Global Pharma can accelerate commercial sales and registration in China through Real World Data

Hainan Boao Lecheng special zone is the first area in China where RWD can be widely used. The Lecheng Real World Study (RWS) pathway allows overseas drugs, medical devices, and IVDs with clinical urgency status, that have not been approved by the China NMPA, to be sold and used in real world clinical settings in the Hainan province, China.

Read more